05:28 PM EST, 01/27/2025 (MT Newswires) -- Neurocrine Biosciences ( NBIX ) said it has obtained exclusive rights for all indications to develop and commercialize osavampator for patients with inadequate response to treatment of major depressive disorder following an amended agreement with Takeda Pharmaceuticals.

The rights are for all territories worldwide, except Japan, where Takeda will reacquire exclusive rights, according to a statement late Monday. Each company is responsible for development costs in their respective region, and both companies are eligible to receive royalty payments.